|
||
| |||||||
|
Dowpharma Announces Additional Capabilities
for Nucleic Acid Medicines Production New oligo synthesizer increases speed and flexibility in producing clinical quantities for customers
MIDLAND, MI—(August 3, 2005) — DowpharmaSM contract manufacturing services, a business unit of The Dow Chemical Company, announced today the addition of an oligonucleotide synthesizer, the OligoPilot 400, to its cGMP manufacturing offering in nucleic acid medicines, which spans lab- to commercial-scale, with intermediate capabilities in between.
“With the addition of this synthesizer, we will be better able to meet drug manufacturers’ needs in all areas of production in nucleic acid medicines, offering greater flexibility, speed and convenience,” said Nick Hyde, business director, Dowpharma. “The compatibility between this synthesizer and other Dowpharma assets demonstrates that we continue to enhance our ability to scale up seamlessly to mid-scale and commercial-scale production as customers require larger quantities of their drug product.”
The added capabilities of the OligoPilot 400 synthesizer build on Dowpharma’s ability to meet drug makers’ needs in growing application areas such as RNA interference (RNAi). It will be especially valuable for companies in early toxicology or Phase I or II clinical trials, who need quantities in the 100 gram range.
“I’m pleased that we can offer our customers this new capability that will make their journey through clinical trials more efficient, and minimize potential scale-up or transition risks,” Hyde added. “This addition is another step in our continuing investment in nucleic acid medicines, an area that we believe has significant long-term potential. Dowpharma continues to offer the broadest range of asset capability as well as the largest oligo synthesis capability in the industry.”
About Dowpharma DowpharmaSM contract manufacturing services delivers innovative technologies, products, and services in drug discovery, development, delivery and manufacturing to pharmaceutical and biopharmaceutical companies. Dowpharma has one of the broadest and deepest capabilities in the global outsourcing industry with services that include process development, route selection, methods development, custom solubilization, chiral capabilities, and associated analytical services, as well as manufacturing and scale-up from feasibility, through clinical trials, to commercial manufacturing. Dowpharma manufactures small molecule Active Pharmaceutical Ingredients (APIs) and intermediates, nucleic acid medicines, cGMP polymers, peptides and therapeutic proteins from microbial fermentation and plant-based systems. Dowpharma draws upon over 30 years of excellent cGMP regulatory compliance in the organic synthesis of APIs and pharmaceutical intermediates with the ability to provide client support in filing and validation strategies. Dowpharma operates research, process development, and manufacturing facilities in North America and Europe. More information is available at www.dowpharma.com.
About Dow Dow is a leader in science and technology, providing innovative chemical, plastic and agricultural products and services to many essential consumer markets. With annual sales of $40 billion, Dow serves customers in 175 countries and a wide range of markets that are vital to human progress: food, transportation, health and medicine, personal and home care, and building and construction, among others. Committed to the principles of sustainable development, Dow and its 43,000 employees seek to balance economic, environmental and social responsibilities. References to "Dow" or the "Company" mean The Dow Chemical Company and its consolidated subsidiaries unless otherwise expressly noted.
# # #
SM Service Mark of The Dow Chemical Company TM Trademark of The Dow Chemical Company
For more information: Kathleen Davis Dowpharma The Dow Chemical Company +1 989-636-2760
Josiah McClellan
Gibbs & Soell
+1
212-697-2600
|
|
| ||||||||